The Quantellect read.As of Nov 19, 2026, 24 active firms cover Medline Inc. Class A Common Stock: 20 rate it Buy or better, 4 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $34.00 to $55.00, a moderate spread. The average target of $46.91 sits 20% above the current $39.16. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.34 next quarter toward $1.54 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 active firms
Buy
Strong Buy00%
Buy2083%
Neutral417%
Sell00%
Strong Sell00%
Based on 24 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.91
+19.8% upside
Average target across 22 active firms as of Nov 19, 2026 vs $39.16 current
Highest Target$55.00
Average Target$46.91
Lowest Target$34.00
Detailed analyst forecasts for MDLN
Showing 1–22 of 22 named analysts shown · 24 active firms in the rating projection
As of Nov 19, 2026, 20 of 24 active firms rate MDLN a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MDLN EPS & revenue forecast
EPS · NEXT QUARTER
$0.34
Range $0.27 – $0.40 · 16 analysts · +3% YoY
Next period, 16 analysts expect Medline Inc. Class A Common Stock to earn $0.34 a share (range $0.27 – $0.40), versus $0.33 a year earlier. Full-year consensus is $1.57, growing to $1.54 the year after.
REVENUE · NEXT QUARTER
$7.9B
Range $7.7B – $8.0B · 16 analysts · +7% YoY
Revenue is expected to reach $7.9B (range $7.7B – $8.0B), +7.2% year-over-year. Full-year consensus is $31.4B, rising to $33.9B next year.
Top analysts covering Medline Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDLN.
#1
Stephen Baxter
Wells Fargo · Rank #63
Neutral
$34.00-13.2% to target
Overall win rate
47%
+ Follow
#2
Erin Wright
Morgan Stanley · Rank #81
Buy
$48.00+22.6% to target
Overall win rate
55%
+ Follow
#3
EC
Eric Coldwell
Baird · Rank #127
Buy
$42.00+7.3% to target
Overall win rate
37%
+ Follow
#4
Kevin Caliendo
UBS · Rank #165
Buy
$49.00+25.1% to target
Overall win rate
42%
+ Follow
#5
Jason Bednar
Piper Sandler · Rank #360
Buy
$55.00+40.5% to target
Overall win rate
33%
+ Follow
MDLN stock forecast FAQ
What is MDLN's average 12-month price target?+
The 22 active firms with a live target average $46.91 for Medline Inc. Class A Common Stock over the next 12 months, ranging from a $55.00 high to a $34.00 low, as of Nov 19, 2026.
Is MDLN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 24 active firms as of Nov 19, 2026, 20 rate it Buy or Strong Buy, 4 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MDLN?+
The Street-high target is $55.00 (BTIG), and the Street-low is $34.00 (Wells Fargo). The average of all 22 active-firm targets is $46.91.
How many active Wall Street firms cover MDLN?+
24 active firms have a recognized rating on Medline Inc. Class A Common Stock as of Nov 19, 2026, and 22 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MDLN?+
Among analysts who currently cover MDLN, Stephen Baxter of Wells Fargo has the strongest overall Quantellect track record (Rank #63). Their current call is Neutral with a $34.00 target.
What is Medline Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $0.34 per share (range $0.27 – $0.40) across 16 analysts. Full-year EPS is projected at $1.57, rising to $1.54 the following year.
How much revenue is Medline Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $7.9B (range $7.7B – $8.0B). Full-year revenue is projected at $31.4B, growing to $33.9B next year.
Have analysts been upgrading or downgrading MDLN lately?+
As of Nov 19, 2026, 20 of 24 active firms rate MDLN a Buy (4 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDLN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.